SYN-TECH Chem. & Pharm (1777) Stock Overview
Manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
1777 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
SYN-TECH Chem. & Pharm. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$71.10 |
| 52 Week High | NT$110.00 |
| 52 Week Low | NT$70.50 |
| Beta | -0.14 |
| 1 Month Change | -2.07% |
| 3 Month Change | -8.38% |
| 1 Year Change | -25.63% |
| 3 Year Change | -19.30% |
| 5 Year Change | -6.82% |
| Change since IPO | 252.45% |
Recent News & Updates
Recent updates
SYN-TECH Chem. & Pharm (GTSM:1777) Could Easily Take On More Debt
Mar 19
Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield
Feb 26Declining Stock and Decent Financials: Is The Market Wrong About SYN-TECH Chem. & Pharm. Co., Ltd. (GTSM:1777)?
Feb 05
SYN-TECH Chem. & Pharm's (GTSM:1777) Shareholders Are Down 11% On Their Shares
Jan 10SYN-TECH Chem. & Pharm (GTSM:1777) Seems To Use Debt Rather Sparingly
Dec 19Here's What You Should Know About SYN-TECH Chem. & Pharm. Co., Ltd.'s (GTSM:1777) 4.6% Dividend Yield
Nov 28Shareholder Returns
| 1777 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | 1.5% |
| 1Y | -25.6% | 5.8% | 39.9% |
Return vs Industry: 1777 underperformed the TW Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: 1777 underperformed the TW Market which returned 39.9% over the past year.
Price Volatility
| 1777 volatility | |
|---|---|
| 1777 Average Weekly Movement | 1.4% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 9.1% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1777 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1777's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 227 | n/a | www.syn-tech.com.tw |
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines.
SYN-TECH Chem. & Pharm. Co., Ltd. Fundamentals Summary
| 1777 fundamental statistics | |
|---|---|
| Market cap | NT$3.17b |
| Earnings (TTM) | NT$261.01m |
| Revenue (TTM) | NT$1.29b |
Is 1777 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1777 income statement (TTM) | |
|---|---|
| Revenue | NT$1.29b |
| Cost of Revenue | NT$842.89m |
| Gross Profit | NT$448.68m |
| Other Expenses | NT$187.68m |
| Earnings | NT$261.01m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.85 |
| Gross Margin | 34.74% |
| Net Profit Margin | 20.21% |
| Debt/Equity Ratio | 0% |
How did 1777 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/18 20:35 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SYN-TECH Chem. & Pharm. Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Xiaowei Huang | Masterlink Securities Corp. |